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Revealed by Single-Cell Imaging
Peter Brazda,a,b Jan Krieger,d Bence Daniel,a David Jonas,a,b Tibor Szekeres,c Jörg Langowski,d Katalin Tóth,d Laszlo Nagy,a,b
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Retinoid X receptor (RXR) is a promiscuous nuclear receptor forming heterodimers with several other receptors, which activate
different sets of genes. Upon agonist treatment, the occupancy of its genomic binding regions increased, but only a modest
change in the number of sites was revealed by chromatin immunoprecipitation followed by sequencing, suggesting a rather
static behavior. However, such genome-wide and biochemical approaches do not take into account the dynamic behavior of a
transcription factor. Therefore, we characterized the nuclear dynamics of RXR during activation in single cells on the subsecond
scale using live-cell imaging. By applying fluorescence recovery after photobleaching and fluorescence correlation spectroscopy
(FCS), techniques with different temporal and spatial resolutions, a highly dynamic behavior could be uncovered which is best
described by a two-state model (slow and fast) of receptor mobility. In the unliganded state, most RXRs belonged to the fast pop-
ulation, leaving15% for the slow, chromatin-bound fraction. Upon agonist treatment, this ratio increased to43% as a result
of an immediate and reversible redistribution. Coactivator binding appears to be indispensable for redistribution and has a ma-
jor contribution to chromatin association. A nuclear mobility map recorded by light sheet microscopy-FCS shows that the li-
gand-induced transition from the fast to the slow population occurs throughout the nucleus. Our results support a model in
which RXR has a distinct, highly dynamic nuclear behavior and follows hit-and-run kinetics upon activation.
Transcription is an inherently dynamic process. Paradoxically,mostmodels of transcription factor (TF) behavior assume that
TFs are bound to chromatin either permanently or with a fairly
long residence time upon activation (seconds to minutes). Recent
advances in genomic technologies, such as chromatin immuno-
precipitation followed by sequencing (ChIP-Seq), also provided
support to such static models (1, 2). However, these methods lack
the appropriate time resolution to provide insights into the dy-
namics of activated transcription factors on the time scale of sec-
onds or shorter.
Nuclear receptors (NRs) can directly bind to DNA via their
highly conserved DNA-binding domain (DBD), which is near
their N termini. High-affinity binding is made possible by the two
zinc finger motifs. This domain recognizes the specific hormone
response elements (RE) (3), which are binding sites and/or en-
hancers regulating transcription of target genes. A consensus RE
sequence is AGGTCA (4), which acts as a half site (binds one
receptor) for homo- or heterodimer binding. The hinge region of
the receptor that gives a high degree of flexibility to the overall
structure is located next to the DBD. This part of the protein
harbors the nuclear localization signal (NLS) as well. The core of
nuclear receptor action lies in the ligand-binding domain (LBD),
through which dimer formation, ligand binding, coregulator
binding, and trans activation occur. Retinoid X receptor (RXR)
belongs to the nuclear receptor superfamily and is unique in its
ability to act as an obligate heterodimeric partner for many other
receptors. The molecular basis of this promiscuous activity is not
well understood.
According to the rather static “molecular switch” model, core-
pressors and members of the repressor complex, including his-
tone deacetylases (HDACs), are bound in the absence of ligand to
the NR, which is believed to associate with chromatin (3, 5–8).
Upon agonist binding to the LBD, the NR goes through confor-
mation changes. The affinity of the agonist-bound holo form de-
creases to corepressors and increases to coactivators. As a result, a
new set of proteins is bound to the receptor, an activator complex,
including histone acetyltransferases (HATs). It is not a far-fetched
assumption that coregulator binding has a major effect on chro-
matin binding, but its contribution to this process is not fully
understood.
Recently, ChIP revealed a novel dynamic feature of nuclear
receptors. It was found that during estrogen receptor action, un-
productive cycles marked by rapid DNA binding alternate with
ligand-dependent productive cycles characterized by reduced re-
ceptormobility and longer binding times (9). Fluorescence recov-
ery after photobleaching (FRAP) was among the first methods
allowing the study of transcription dynamics by detecting mobil-
ity in the subsecond range (10, 11). Such studies represented the
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first challenge to the rigid/staticmodel and led to the proposal of a
“hit-and-run” model, which was based on the analysis of variable
immobile fractions and half-recovery times of the bleached fluo-
rescence signals of fluorophore-tagged NRs in FRAP experiments
(12). Approaches like FRAP ignited interest in studying the kinet-
ics of transcription regulation with greater time resolution. Fluo-
rescence correlation spectroscopy (FCS) utilizes the fluctua-
tion of fluorescence intensity resulting from the diffusion of
fluorescently tagged molecules in and out of a confocal (sub-
femtoliter-sized) volume. With FCS, one can characterize the
diffusion properties of molecular subpopulations at millisec-
ond time resolution (13, 14).
We aimed to determine the dynamic properties of the RXR
receptor upon ligand activation and integrate results derived from
different experimental approaches. Using ChIP-Seq, we found
that the genomic regions to which RXR bound were largely the
same before and after agonist treatment, but the occupancy of
these regions by RXR increased. FRAP showed that ligand activa-
tion induced slowing of the half-recovery time, but immobilized
receptors were not detected. FCS provided insights into the sub-
second range. The diffusion dynamics of the receptors were inter-
preted by a two-component normal diffusionmodel representing
a fast and a slow component. The slow component most likely
represents (transient) DNA binding, which showed a ligand-in-
duced immediate and reversible increase. Importantly, coactiva-
tor binding appears to be amajor determinant of the shift between
the two states.
MATERIALS AND METHODS
Cell culturing, plasmids, and transfection assays. Cell culturing, plas-
mids, and transfection assays are described in the supplemental material.
ChIP. ChIP was performed as previously described (15), with minor
modifications. Briefly, cross-linking was carried out by disuccinimidyl
glutarate for 30 min and by formaldehyde (Sigma) treatment for 10 min
and was followed by RXR immunoprecipitation. After fixation, chroma-
tin was sonicated with a Diagenode Bioruptor to generate 200- to
1,000-bp fragments. Chromatinwas immunoprecipitatedwith antibodies
against preimmune IgG (12-370;Millipore) and RXR (sc-774; Santa Cruz
Biotechnologies, Inc.). Chromatin antibody complexes were precipitated
with protein A-coated paramagnetic beads (Life Technologies). After 6
washing steps, complexes were eluted and reverse cross-linked.DNA frag-
ments were column purified (MinElute; Qiagen). The amount of immu-
noprecipitated DNA was quantified with a Qubit fluorometer (Invitro-
gen). DNA was submitted to quantitative PCR (qPCR) analysis or library
preparation. ChIP-seq library preparation and data analysis are described
in the supplemental material.
Real-time RT-PCR and immunofluorescence detection. Real-time
reverse transcription-PCR (RT-PCR) and immunofluorescence detection
are described in the supplemental material.
FRAP. FRAP measurements were performed on an Olympus Fluo-
View 1000 confocal microscope based on an inverted IX-81 stand with an
UPlanAPO 60, 1.2-numeric-aperture (NA) water immersion objective.
The 488-nm line of an Ar ion laser excited enhanced green fluorescent
protein (EGFP), and emission was detected through a 500- to 550-nm
band-pass filter. For quantitative analysis, a 256- by 256-pixel area was
selected and scanned with an open pinhole and 10 zoom (pixel size, 82
nm). Before each measurement, 10 prebleach images were taken with 1%
laser intensity (9 W) followed by a 1,500-ms bleach period with 100%
laser intensity (900 W) within the bleach area of 256 by 10 pixels that
covered less than 30% of the whole nucleus. Fluorescence pixel intensities
of background (outside the cell), region of interest (ROI; i.e., the bleached
strip), (the strip), and whole nucleus (the nucleus including the strip but
excluding the nucleoli) were determined for each frame with NIH ImageJ
v.1.45s. Recovery curves were created, normalized, and evaluated with
IGOR software using Phair’s double exponential model in the FrapCalc-
EMBL module (version V9h).
FCS instrumentation and measurements. FCS measurements were
performed on themicroscope described above. The 2-channel FCS exten-
sion (prototype designed by Jörg Langowski, DKFZ, Heidelberg, Ger-
many) is attached to the 4th detection channel of the confocal scanning
unit. FCS measurements on live HeLa cells were performed in 8-well
chambered coverglass plates as described above. Fluorescence of EGFP
was excited by the 488-nm line of an Ar ion laser, and emission was
detected through a 500- to 550-nm band-pass filter by a Perkin-Elmer
avalanche photodiode (Perkin-Elmer, Wellesley, MA). Fluorescence au-
tocorrelation curves were calculated online by an ALV-5000E correlator
card (ALV-Laser Vertriebsgesellschaft mbH, Langen, Germany). Mea-
surements of 10 8-s runs were taken at three selected points in the nucleus
of each selected cell. FCS data acquisition and processing are described in
the supplemental material.
SPIM-FCS measurements. Single-plane illumination microscopy
(SPIM)-FCS measurements were performed on a custom-built setup de-
scribed in reference 16. A 491-nm DPSS laser is magnified 5-fold (1 to
8 zoom beam expander) and then relayed (additional 3 magnifica-
tion) onto a cylindrical lens (focal length [f], 100 mm). An air projection
objective (10 magnification, 0.3 NA; Plan Fluor; Nikon) projects a light
sheet into a stainless steel, water-filled sample chamber. Samples are
mounted on amotorized XYZ stage. Detection is done using a Nikon CFI
Apo-W NIR (60, 1.0 NA) water-dipping objective. Emitted light is fil-
tered by a 500- to 550-nm band-pass filter. Fluorescent light is imaged
onto an iXon X3 860 electron-multiplying charge-coupled device camera
(Andor, Belfast, United Kingdom) using a Nikon tube lens (f, 200 mm).
The camera has a pixel size of 24 by 24 m2, corresponding to 400 by 400
nm2 in the object plane. Adherent HeLa cells were grown on small (5 by
10 mm2) pieces of no. 3 coverslips and mounted from above in the sample
chamber. The chamber was filledwith phenol red-free RPMImedium.Mea-
surements were performed at room temperature (24°C). SPIM-FCS data
acquisition and processing are described in the supplemental material.
RESULTS
Agonist treatment increases genomic binding site occupancy of
RXR at the whole-genome level. We first decided to determine
the number of binding sites that RXR occupies and the impact of
ligand on that in our HeLa-based model system. Chromatin
immunoprecipitation followed by next-generation sequencing
(ChIP-seq) was performed using HeLa cells treated with a selec-
tive RXR agonist (100 nMLG100268) for 1 h. Samples were cross-
linked and immunoprecipitated by a pan-RXRantibody. Libraries
were generated from the precipitatedDNA,whichwere sequenced
and thenmapped back to the genome. The genomic locations that
showed RXR binding were defined as RXR genomic binding sites.
These are typically referred to as peaks, because stacks of short
sequences show up as peaks on genome browsers when the data
are visualized. Peaks were identified by the Homer2 software. A
total of 6,636 genomic regionswere determined as binding regions
in the control (vehicle-treated) samples. This number increased
modestly in the LG268-activated samples, where 8,302 binding
sites were detected. A total of 5,138 (more than 50%) of all peaks
were identical before and after agonist treatment. These are the
sites that appear to be occupied by RXR irrespective of ligand
treatment (Fig. 1A). A total of 1,498 sites disappeared, and 3,164
new sites appeared upon activation. The relative position of the
two half sites is one important element in the heterodimer selec-
tion. Different heterodimers prefer certain direct repeats (DR0 to
RXR’s Dynamic Nuclear Behavior












FIG 1 Addition of agonist ligand causes an increase in the probability of chromatin binding. (A) Genomic locations identified as RXR-occupied sites using
ChIP-seq in control (vehicle-treated) and agonist (LG268)-treatedHeLa cells. The numbers of binding regions determined byHomer2 are plotted. The peak sets
of control and LG268-treated samples were compared. The peaks unique for just one state and those common for both states are presented in the Venn diagram.
(B and C) Contribution to the different motif sets of NR-binding elements present only in the control sample (B) or only in the LG268-treated sample (C). DR,
direct repeat; ER, everted repeat; IR, inverted repeat. Numbers represent the number of spacers between the half-sites of the repeats. (D and E)Motif analysis of
theNR binding sites found at the genomic locations shown in panels B andC. The top threemotifs are shown according to their strength determined byHomer2.
Values next to the motifs represent the fraction of sequences that contained that motif from all of the peaks. (F) Histograms representing the average genome-
wide occupancy of RXR binding sites. The500 bp flanking the highest peak position of the RXR-binding genomic regions are shown. The binding sites present
in both the control- and agonist-treated samples (represented by the intersection of the Venn diagram in panel A) were considered for the presented cumulative
peaks. Values are normalized relative to the control data. agonist, LG268 treated.
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DR5). TheDR, everted repeat (ER), and inverted repeat (IR) pref-
erences of RXR are presented in Fig. 1B (control) and C (LG268
treatment). These diagrams represent the relative distribution of
sites occurring only in the control sample (1,498 sites from Fig.
1A) and those occurring exclusively in the LG268-treated sample
(3,164 sites from Fig. 1A). Absolute numbers of these sites as well
as sites shared by both samples are shown in Fig. S1A in the sup-
plemental material. As expected, DRs are dominant among the
identified genomic regions. The distribution of the various DRs
did not change upon agonist treatment. Sequence motifs under
the peaks (i.e., the genomic locations where RXR was bound)
included the consensus AGGTCA half-site sequence of response
elements (REs) (Fig. 1D and E). The values in percentages repre-
sent the frequency of a motif being detected at the binding site.
This value is around 50%, meaning that from all sites where RXR
was bound, in 50% of the cases there was a bona fide half-site
found. The remaining 50% might include loop formation and
tethering/cobinding events with other factors (indirect binding)
or direct RXR binding at sites with weaker similarity to the NR
half-sites. The distributions of the most frequently found motifs
were nearly identical before and after agonist treatment.
Figure 1F shows the histogram of genome-wide distribution of
RXR binding sites that are identical before and after agonist treat-
ment (the intersection shown in Fig. 1A). The heights of these
cumulative peaks are proportional to the overall probability of
RXR being found at the detected genomic locations; therefore, they
characterize chromatin occupancy. The maximum tag count num-
berof thepeaks increased from28to39(withmeanvalues from9.3 to
12, respectively). Thus, within 1 h, ligand activation increased the
probability of RXR binding to DNA or chromatin. It is important to
emphasize two major issues about this method. First, only bound
receptors are detected; because fixation immobilizes receptors on the
chromatin, it records an average over the time period of the fixation
process of receptor localization. Second, the results obtained here are
population averages of millions of cells.
Expression, distribution, and functionality of GFP-tagged
RXR. In order to determine the subcellular distribution and ex-
pression level of RXR, we studied EGFP-RXR and its truncated
form (referred to as GFP-RXR and GFP-RXR-LBD) in HeLa cells
using confocal microscopy. GFP-RXR-LBD has the ligand-bind-
ing domain but lacks the DNA-binding domain and the NLS.
Expression of the full-length construct was tested by Western
blotting (see Fig. S2A in the supplemental material). Coregulator
binding and transactivation capacity of GFP-fused constructs
were documented by luciferase-based transient-transfection as-
says (see Fig. S2B to D in the supplemental material). Confocal
microscopy revealed that full-length GFP-RXR was localized in
the nucleus, while GFP-RXR-LBDwas distributed homogenously
in the cell (Fig. 2A). A cell line stably expressing GFP-RXR was
used for further analyses to avoid heterogeneity of the expression
level typical for transient transfection. Excessive overexpression
could skew binding equilibria of the interacting protein. There-
fore, we measured the expression levels in wild-type and GFP-
RXR-transfected cells. Real-time quantitative PCRproved that the
transfected NRs did not lead to superphysiological levels of ex-
pression; themRNA level of RXR increased3-fold (Fig. 2B). The
expression level of other tested genes (for retinoic acid receptor 
[RAR] ACTR [activator for nucleic acid receptors/SRC-3/
NCoA3], and SMRT [silencing mediator of retinoic acid and thy-
roid hormone receptor/NCoR2]) remained unchanged. We also
compared the relativeRXRprotein expression levels in transfected
and wild-type cells by immunofluorescence (Fig. 2C). The ratio
was 1.3, indicating that the transfected cells had near-physiologi-
cal levels of RXR. As usual, this value sets the lower limit of the real
expression ratio, because possible unspecific binding of the pri-
mary antibody could not be taken into account. The nuclear dis-
tribution of endogenous and exogenous (GFP-tagged) RXR was
similar in comparisons of immunostained HeLa and HeLa-GFP-
RXR cells (see Fig. S3 in the supplemental material). In both cases,
homogenous nuclear distribution was observed.
GFP-RXR slows down during activation as determined by
FRAP. The intracellular mobility of RXR was studied by FRAP,
FIG 2 Characterization of the HeLa-GFP-RXR cell line. (A) Distribution
of GFP-RXR and GFP-RXR-LBD expressed in HeLa cells recorded by live-
cell confocal microscopy. Scale bar, 10 m. (B) mRNA levels of nuclear
receptors and cofactors measured by RT-qPCR in the wild-type HeLa cells
and HeLa cell line stably expressing GFP-RXR. Results were normalized to
the level of human cyclophilin. (C) RXR protein level of wild-type HeLa
cells and cells stably transfected with GFP-RXR as detected by immunoflu-
orescence. Intensities were corrected for unspecific binding of the second-
ary antibody and autofluorescence. s.d., standard deviation.
RXR’s Dynamic Nuclear Behavior












which allows analysis of RXR dynamics on the scale of seconds.
The two issues we wished to resolve with this method were (i)
whether an immobile fraction appears after ligand treatment and
(ii) how the increased DNA-binding probability detected by
ChIP-seq is revealed at the single-cell level.
In the absence of ligand, the fluorescence signal in the nuclear
ROIs showed rapid recovery after bleaching with a half-recovery
time (t1/2) of 2.5  0.4 s, and essentially no immobile fraction
(3% 3%) was detectable. Ten minutes after the addition of 100
nM LG268, the t1/2 increased to 7.3 0.7 s, but still no significant
immobile fraction was detected (7%  3%). Agonist treatment
also caused an increase, although to a lesser extent, in the t1/2 of
GFP-RXR-LBD that lacks direct DNA-binding ability (Fig. 3). In
these FRAP experiments, slowing down of RXRwas detected dur-
ing activation, but unlike several other NRs, RXR did not form an
immobile fraction that would indicate a longer DNA residence
time. This finding agrees with earlier results from different cell
lines (17). For these analyses, recovery curves were fitted to a dou-
ble exponential assuming two diffusing species. The time con-
stants of the components and their fractional amplitudes are
shown in Fig. S4 in the supplemental material. In the unliganded
state, the fast component of GFP-RXR comprised 45% of the
population, which increased to 65% upon agonist treatment
(see Fig. S4C in the supplemental material). The time constants of
both the slow and the fast populations also increased significantly.
For GFP-RXR-LBD, both components had significantly shorter
time constants than full-length receptors, but a similar increase in
the time constants occurred upon agonist treatment. On the other
hand, the agonist-induced change of the fractional amplitudes
was smaller than that for GFP-RXR.
FCS analysis of RXR mobility at the subsecond scale. To
move one step further down the time and distance scales and
quantify the mobility parameters of RXR in the millisecond time
and submicrometer distance ranges, we applied FCS.We analyzed
the fluorescence autocorrelation functions (ACFs) with one- and
two-component models of normal and anomalous diffusion (see
Fig. S5 and Table S1 in the supplemental material). A single diffu-
sion component with normal diffusion gave a poor fit; introduc-
tion of a second component improved the fit significantly. There-
fore, we chose the two-component normal diffusion model (Fig.
4A) for representing the data. In the model function, triplet state
formation and another slower dark state, due to protonation, were
also taken into account (18). Results of anomalous diffusionmod-
els are discussed below (see Fig. S5B to E in the supplemental
material).
The ranges of the diffusion timeswere between 1 0.8 to 3ms
for the fast component and 2  20 to 120 ms for the slow com-
ponent (with corresponding diffusion coefficients ofD1 3 to 12
m2/s andD2 0.07 to 0.5m
2/s) (Fig. 4B, 7th and 9th columns).
When these diffusion times were converted into apparent masses
[using the Stokes-Einstein relation, D kT/(6	
R) for spherical
objects and assuming proportionality of molecular mass to R3,
where k is the Boltzmann’s constant, T is the absolute tempera-
ture, 
 is viscosity, and R is molecular radius], the slow compo-
nent gave a 106-fold larger mass than the real molecular mass of
the GFP-fused nuclear receptor. This difference most likely re-
flects both an increased molecular mass of the receptor complex
and/or the crowded nuclear environment and the interactions of
RXR with the chromatin (possibly as part of larger protein com-
plexes). A histogramof the distribution of the diffusion times (Fig.
4C) shows the relative sizes of the two populations and their re-
spective diffusion times (for r2, 16% of GFP-RXR molecules be-
long to the slow population, the large majority; for r1, 84% belong
to the fast one). The high fraction of the fast population is not an
artifact due to overexpression, as evidenced by the fact that in
stably transfected GFP-RXR HeLa cells, neither the diffusion
times nor the ratios of the two components depended on the num-
ber of molecules in the detection volume (see Fig. S6A to C in the
supplemental material). To determine whether the fast popula-
tion of GFP-RXR consists of freely diffusing molecules, its diffu-
sion time was compared to that of GFP oligomers (Fig. 4B, 1st,
2nd, 3rd, 5th, and 7th columns). The diffusion coefficients of tri-
meric GFP (with an estimated molecular mass of 81 kDa) and the
fast time of GFP-RXR (with an estimated molecular mass of 78
kDa) were similar. From these results, we conclude that the fast
population of GFP-RXR diffuses without considerable DNA
binding, whereas the slow population interacts with chromatin.
Agonist-dependent changes in RXRmobility are immediate
and reversible.RXRplays a central role in nuclear receptor action,
forming heterodimers with many different binding partners. The
molecular switch model describes receptor-coregulator and re-
ceptor-DNA interactions mainly regulated by the agonist ligand.
Our question was how ligand-dependent activation and coregu-
lator exchange are reflected in the mobility of RXR. The redistri-
bution of the populations appeared already in the first FCS mea-
surement following activation taken 5 min after the addition of
agonist ligand. The ratio of the slow (second) population in-
creased from 16% to 43%, and the distribution of the fast diffu-
sion time shifted to larger values. The mean of the slow diffusion
time increased slightly, and its distribution broadened (Fig. 4C).
The shift of the related autocorrelation curves is shown in Fig. 4D.
To show that this effect is RXR agonist specific, we carried out
similar measurements with various agonists of related nuclear re-
ceptors. Neither the RAR agonist (AM580) nor the peroxisome
proliferator-activated receptor gamma (PPAR) agonist ligand
FIG 3 RXR mobility at the minute time scale depends on ligand and DNA
binding as revealed by FRAP analysis. Fluorescence recovery curves and half-
recovery times of GFP-RXR and GFP-RXR-LBD in the absence () and pres-
ence () of 100 nM LG268. Data are means  standard deviations. Red bar
versus green bar, P 0.01; blue bar versus black bar, P 0.001.
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(rosiglitazone) caused an increase in the size of the slow popula-
tion (r2); only ligands described as RXR agonists (LG268 and 9-cis
retinoic acid) did (Fig. 5A). As an attempt to reveal the kinetics of
the effect, we carried out a time-lapse experiment. The effect was
detectable already at our first time point (4 min) (Fig. 5B). The
effect was dose dependent (Fig. 5C). Based on these and earlier,
luciferase assay-based activationmeasurements, we decided to ap-
ply LG268 agonist at a 100 nM concentration. To rule out an
agonist-dependent global viscosity change of the nucleus, we
compared the diffusion coefficients of 3 GFP and 4 GFP with
or without LG268. Diffusion coefficients of all the GFP-related
experiments are summarized in Fig. 4B. The GFP oligomers
showed no change in their diffusion, which implies that ligand-
induced effects were specific for RXR. Confocal images of the
distribution of GFP oligomers and GFP-RXR with or without
ligand treatment are shown in Fig. S7A in the supplemental
material.
We found earlier that the agonist-dependent redistribution of
RAR (a heterodimer partner of RXR) was not reverted when the
ligand was removed from the medium (13), implying a low off-
rate in the receptor-chromatin interaction. In contrast toRAR, the
redistribution of the two RXR populations was reverted com-
pletely when the agonist was removed from the medium (Fig. 5A,
last column). This experiment was repeated using 9-cis retinoic
acid and gave the same result, indicating that the agonist effect was
reversible (Fig. 5D). Interestingly, transition to the slow state oc-
curred repeatedly after a second ligand treatment (last column).
Coactivator binding has a large impact on the diffusion of
activated RXR. NRs directly connect extra- and intracellular sig-
nals with the chromatin through protein-ligand, protein-DNA,
and protein-protein interactions. Studying the effect of coregula-
tor binding on the mobility of RXR in live cells provides crucial
information on NR action in the framework of the molecular
switch model. Thus, we fused the interaction domains (ID) of
either the SMRT corepressor or the ACTR coactivator to a con-
sensus nuclear localization signal and an mCherry fluorophore
(mCherry-NLS-SMRT-ID/repressor peptide and mCherry-NLS-
ACTR-ID/activator peptide). The expressed peptides can still rec-
ognize and bind RXR but lack the domain necessary for binding
additional members of the large coregulator complexes. As such,
they act as competitive inhibitors of endogenous coregulator
complexes by preventing full-length coregulators and additional
members of the complex from binding there. One or the other
short peptide was cotransfected along with GFP-RXR, the diffu-
sion of which was then measured (Fig. 6A). Expression levels of
the tagged proteins were monitored via their fluorescence signal.
With no ligand added, cotransfection of the ID peptides did not
change the size of the fraction of the slower population. Treatment
with LG268 in the presence of the repressor peptide caused a tran-
sition to the slow state similar to that observed earlier. On the
other hand, no ligand-induced redistribution occurred when the
activator peptidewas cotransfected (last column). The presence of
the exogenous activator IDs prevented endogenous coactivator
binding; thus, the slowing down of RXR could not take place. This
FIG 4 Fraction of the slower population increases rapidly upon agonist treatment according to FCS. (A) Autocorrelation curve [G()] of a representative
experiment (black) fitted with the two-component, normal diffusion model (red). , lag time. (B) Diffusion coefficients of 1 GFP, 2 GFP, 3 GFP, and 4
GFP (with or without agonist) oligomers fitted with a one-component free-diffusionmodel compared to the diffusion coefficients of GFP-RXR (with or without
agonist) fitted with the two-component normal diffusion model (fast component and slow component). LG268, treatment with 100 nM for 10 min. (C)
Distribution of diffusion times (D) of GFP-RXR before (no ligand) and 10 min after (LG268) the addition of 100 nM LG268. (D) Normalized autocorrelation
curves of a representative experiment (n 30).
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phenomenon fits well in our general concept of NRs, where the
main event of activation is the binding of the activator complex.
The repressor peptide was displaced by the coactivator complex
upon ligand binding; thus, RXR slowed down. However, forma-
tion of coactivator complexes was probably blocked via competi-
tive inhibition by the activator peptides, implying that binding of
full-length coactivator is essential for the ligand-dependent slow-
ing down of RXR. This also means that the chromatin-binding
affinity of the receptor in the activator complex is larger than in
the absence of ligand (when the receptor is either in a repressor
complex or diffuses freely).
The effect of coactivator binding onRXRmobilitywas tested in
another set of experiments as well. LG1208 is a synthetic (RXR-
specific) ligand that acts as a competitive antagonist (19, 20). Its
effect was tested in the mammalian two-hybrid system, where the
affinity of RXR to coregulators was measured in the presence or
absence of ligands. LG1208 did not significantly alter the corepres-
sor binding ability of RXR (see Fig. S8 in the supplemental mate-
rial); however, unlike an agonist ligand, it failed to enhance the
coactivator binding affinity of RXR. In a dual-ligand treatment,
LG1208 diminished the LG268 effect when it was applied in 10-
fold excess (see Fig. S8B). Summing these effects up, we assume
that LG1208 occupies the ligand-binding pocket of the receptor,
which induces a conformation of RXR incompatible with coacti-
vator binding. These findings were corroborated by FCSmeasure-
ments. The antagonist alone did not change r2, but in combina-
tionwith the agonist ligand (LG268plus LG1208), it prevented the
agonist-induced redistribution (Fig. 6B). This supports our find-
ing that coactivator binding is a prerequisite for the mobility shift
of RXR.
Direct DNA binding has a smaller impact on RXR mobility
than indirect DNA binding or coactivator binding. Due to the
fact that RXR is a transcription factor, one of its key characteristics
is direct DNA binding. Therefore, we expected that abolishing the
DNA binding affinity of the receptor would have amajor effect on
its diffusion. A truncated form of the receptor that contains only
the LBD (i.e., lacking the DBD) was fused to GFP (GFP-RXR-
LBD). Our FRAP measurements already showed that this trun-
cated form had a substantially highermobility than the full-length
receptor, still it responded to activation with an increased half-
recovery time (Fig. 3). This mutant is still capable of ligand and
coregulator binding and dimer formation but is unable to bind to
DNA directly. It is important to emphasize, though, that DNA
binding of the GFP-RXR-LBD construct via the (full-length, en-
dogenous) dimer partners of RXR cannot be excluded. The FCS
measurements in the nucleus showed a slightly shorter diffusion
FIG 5 Characterization of the effect of LG268 on the diffusion of GFP-RXR according to FCS. (A) Fraction of the slow population (r2) before and 10 min after
addition of vehicle or 100 nM AM580, rosiglitazone, LG268, or 9-cis retinoic acid or after the replacement of the LG268-containing medium with the
vehicle-containing one. Data are means standard deviations. (B) Fraction of the slow population (r2) before and 4, 8, 12, 16, and 20 min after addition of 100
nM LG268. (C) Fraction of the slow population (r2) before or 10 min after addition of (10
9 to 106 M) LG268. (D) Fraction of the slow population (r2) before
and 10 min after addition of 100 nM 9-cis retinoic acid, after the replacement of the 9-cis retinoic acid-containing mediumwith the vehicle-containing one, and
after the second 9-cis retinoic acid administration. ***, P 0.001 in all panels; n.s., not significant.
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time for the fast population than GFP-RXR (Fig. 6C). This can be
related to the smaller molecular mass of the truncated receptor.
The apparent diffusion time of the slow component did not differ
significantly from that of GFP-RXR, but its fraction (10%) was
smaller than that of the full-length form. This difference in the
slow fractions implies that DNAbinding or chromatin association
occurs in the unliganded state of the full-length RXR, in accor-
dance with its role in corepressor complexes. Interestingly, as the
agonist was added to the transfected cells, the slow fraction of
GFP-RXR-LBD changed similarly to the full-length receptor; r2
increased to 40% (Fig. 6D). According to our FCSmeasurements,
direct DNA binding influences the mobility of RXR; however,
probably due to its numerous interacting partners (receptors and
coregulators), coactivator (and probably indirect DNA binding)
binding is the essential element for the slowing down during acti-
vation.
Parallel mobility measurements by SPIM-FCS reveal that
RXR’s dynamic properties are similar throughout the nucleus
during activation. Finally, to visualize the spatial distribution of
the mobility of RXR and the effect of activation, we used single-
plane illumination microscopy FCS (SPIM-FCS). The advantage
of single-plane illumination with detection in the entire image
plane is that not just one but a whole set (up to 40 by 20) of FCS
autocorrelation functions can be determined simultaneously in a
single experiment. By fitting these curves, a nuclear mobility map
of RXR can be constructed. As shown in Fig. 7, the fraction of the
slowly diffusing RXR increased after LG268 treatment in the full-
length as well as in the LBD form. In most cells, the localization of
GFP-RXR-LBD changed upon ligand treatment: the initially ho-
mogeneous distribution was replaced by a more pronounced nu-
clear localization. As presented in the mobility map of the slow
component, the unliganded state of the truncated form had a
small slow population. As LG268was applied, the slow population
increased. Thus, the redistribution detected by FCS was con-
firmed and refined by SPIM-FCS. In addition, it was revealed that
the distribution of populations appeared rather homogenous; no
nuclear architecture related pattern could be recognized either
before or after activation.
DISCUSSION
Genome-widemethods refine ourmodels andunderstanding of
transcription factor action. NRs contribute to signal transduc-
tion by directly connecting lipid mediator levels and gene expres-
sion. Their structures allow them to interact with different ligand
molecules, regulatory proteins, and the DNA at the same time,
making them ideal regulatory tools. However, their dynamic be-
FIG 6 Coactivator binding and direct or indirect DNA binding is needed for the agonist-induced slowing of RXR. (A) FCS-derived fractions of the slow
population (r2) of GFP-RXR alone or with the cotransfection of a repressor peptide (mCherry-NLS-SMRT-ID12) or an activator peptide (mCherry-NLS-
ACTR-ID12) before no ligand and 10 min after the addition of 100 nM LG268. Data are means  standard deviations. ***, P  0.001 for all panels. (B)
FCS-derived fractions of the slow population (r2) of GFP-RXRbefore and 10min after the addition of 100 nMLG268, the addition of 1MLG1208 (antagonist),
and the coadministration of the two. (C) Distributions of diffusion times of GFP-RXR-LBD molecules before (GFP-RXR alone) and 10 min after ( repressor
peptide) the addition of 100 nM LG268 are shown and are compared to the wild-type form ( activator peptide). (D) FCS-derived fractions of the slow
population (r2) of GFP-RXR-LBD before and 10 min after the addition of 100 nM LG268 or 100 nM AM580 (RAR agonist).
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havior upon activation is not well characterized.Many of theNRs’
interactions have been extensively studied. The identity of the in-
teracting partners and potential ligands may be tested by various
two-hybrid studies, and transfection-based assays identified re-
sponse elements. Their function can be analyzed using electro-
phoretic mobility shift assay (EMSA) and enhancer/trap experi-
ments.
These in vitro biochemical approaches provide information
about the steady state, and they average the observed activity of
millions of cells. However, cellular processes, especially transcrip-
tion, are very dynamic. Very often a protein spends most of its
time in low-affinity interactions with elements of the genome
rather than binding to its specific sites, which results in a highly
mobile and dynamic system (21, 22).
ChIP experiments (9, 23–25) raised the possibility that TF pop-
ulations with different dynamic properties could coexist, repre-
senting rapid DNA binding-unbinding (detectable by FRAP) and
long-term engagement (referred to as productive engagement) on
a promoter along with other TF partners, resulting in slower mo-
bility (detected by ChIP).
An enigma in understanding TF dynamics is still the connec-
tion between biochemical and genome-wide assays on the one
hand and between genome-wide and single-cell assays on the
other. Here, we studied the effects of transcriptional activation on
RXR’s behavior at different spatial and temporal resolutions.
ChIP coupled with high-throughput sequencing enabled us to
identify the DNA binding regions at the whole-genome scale. The
overall number of RXR-occupied sites increased upon ligand ac-
tivation. Analysis of the genome-wide distribution of RXR bind-
ing sites revealed an increase in the probability of RXR being
bound to these DNA elements, resulting in increased occupancy
after activation. These experiments provided a population and
time average of the changes during RXR activation, as millions of
cells were processed together. To study the observed affinity
change in more detail and with a better time resolution, we ap-
plied fluorescence microscopy methods, which also allow single-
cell detection.
From genome-wide to single cell. According to previous
FRAP measurements, NRs can be divided into two groups based
on their response to activation. Androgen receptor (26) and estro-
gen receptor (27) become immobile after activation, while no im-
mobile fraction appears in the case of glucocorticoid receptor
(28), PPAR, vitamin D receptor (29), RAR, and RXR (30, 31). We
confirmed the latter result in our model system. No long-term
RXR binding was detectable, but a clear increase in recovery time
was detectable on the time scale of seconds, corresponding to the
slowing down of diffusion on the micrometer scale. The ligand-
dependent change in recovery timewas also seenwhen theDBDof
the receptorwas removed, rendering it unavailable for directDNA
binding. This led us to investigate whether interactions other than
those betweenDNA and the receptor significantly affect RXRmo-
bility.
By applying FCSwe achieved a time resolution ofmilliseconds.
FCSwith otherNRs andDNAbinding proteins showed thatmod-
els with either one-component anomalous diffusion (PPAR [32])
or two-component normal diffusion (HP1 [33], RAR [13], Fos-
Jun [34, 35]) could fit the data. This ambiguitymore likely reflects
the limitations of the method rather than the diversity of NR ac-
tion.
FCS fit models attempt to describe the dynamics of a multi-
component system. Even an inert macromolecule such as GFP
exhibits anomalous diffusion, with an anomaly parameter () of
0.85 inside the nucleus (36–38) or in solution packed withmac-
romolecules (39). Macromolecules that interact with multiple
other species most probably exist in various states with different
mobility, contrary to what a one-component model assumes. In
our system, RXR showed the best fit with at least two diffusion
components, meaning that at least two distinct populations of
RXR could be distinguished based on their mobility by FCS. Al-
though a two-component anomalous diffusionmodel fits the data
slightly better, the values of the fit parameters become more un-
certain without changing the most important conclusions. The
major effect discussed in this study, the slowing down of receptor
diffusion upon ligand binding, can be identified in each model.
The first, mobility maps of fluorescent tracer proteins in live
cell nuclei were obtained by Dross et al. (36). Single-plane illumi-
nation fluorescence correlation spectroscopy (SPIM-FCS) probes
in homogeneous three-dimensional environments (40–43), en-
abling the simultaneous measurement of mobility in two-dimen-
sional sections of whole nuclei. The diffusion parameters (diffu-
sion coefficients and fractions of the populations) determined by
imaging FCS measurements showed a good match with those of
single-point confocal FCSmeasurements. Diffusionmaps also re-
vealed that there were no distinct patterns of RXRs with different
diffusion coefficients. This suggested that liganded RXR was not
enriched in so-called transcription factories.
FIG 7 SPIM-FCS reveals a homogenous ligand-induced transition of RXR to
the slow state in the entire nucleus. Cellular map of the fraction of the slow
population (r2) of GFP-RXR and GFP-RXR-LBD in the absence and presence
of ligand. Diagrams display the full range of r2 in the presented cells.
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A refined model of RXR action. Based on these analyses, we
suggest here a refined model of the contribution of the various
interactions to RXR dynamics (Fig. 8). The slowly diffusing pop-
ulation of RXR in the absence of ligand implies direct binding to
DNA or chromatin. Loss of the DBD results in a significant de-
crease of this population. The remaining slow population may
represent the effect of protein-protein interactions or indirect
DNA binding via its dimer partners (Fig. 8, first column). When
direct DNA binding is present (full-length receptor), the fraction
of the slowpopulation increases due to protein-DNA interactions,
although it still remains aminor part of the total. This stage might
represent the scanning motion of NRs when they bind to many
different regions of the genome for short periods of time (Fig. 8,
second column). As agonist appears, RXR changes into its ligand-
bound conformation, which has an increased coregulator binding
affinity compared to that of the unliganded conformation. Re-
sponse element-specific DNA binding and coactivator binding
becomes stronger at this stage (Fig. 8, third and fourth columns).
DNA-RXR interactions probably last longer in this state, but for
the full effect (expansion of the slow state) to take place, binding of
coactivators and further components of the activator complex
seems essential. Surprisingly, this effect also occurs in the absence
of direct DNA binding ability, probably due to the interactions
between RXR and the activator complex (which includes proteins
with direct DNA binding capacity, most probably via the het-
erodimeric receptor partner). This aspect of ourmodel is based on
the inhibition experiments in FCS measurements (with the short
coregulator ID peptides) and the effect of the LG1208 antagonist
on the formation of the coactivator bound state of RXR (Fig. 8,
fifth and sixth columns). When full-length coactivator binding is
inhibited in the system, the fraction of the slow population of RXR
drops to nearly the level of the non-ligand-bound state. The dif-
ference between this state and the non-ligand-bound state (Fig. 8,
second column) might be either the result of incomplete compe-
tition during ourmeasurements or forced dimer formation due to
the presence of the agonist ligand (and the peptide ID binding to
both RXR and RAR).
An interesting aspect of NR activation is that ligand binding
and ligand-induced DNA binding seem to be uncoupled in a cer-
tain sense. When activating RAR-LBD with the specific ligand of
RAR, we got results similar to those described here for RXR-LBD:
the slow fraction of RAR-LBD increased (13). This suggests that
ligand binding at either side of anNRdimer induces the binding of
activator, and the consequent enhancement of DNA binding can
be due to the nonactivated side as well; in other words, ligand
binding andDNA binding can be performed by two distinct com-
ponents of a dimer.
A comparison sheds some light on the difference between
RAR, which has only one potential partner, and RXR, which is
available for many partners and takes part in many interactions.
Compared to RXR, RAR had a larger fraction in the slow state in
the absence of ligand, its ligand-induced increase was less (only
15%), and, contrary to the case of RXR, the change persisted even
after washing out the ligand (13).Moreover, the specific ligands of
neither RXR nor RAR had any significant effect on themobility of
the other receptor. Our interpretation of these differences is that
protein-protein interactions and DNA binding are looser and
more flexible in the case of the promiscuous RXR than for RAR. In
addition, the two receptors may move partially independently
from each other and not necessarily as heterodimers.
Immediate and specific response to various types of stimuli
requires a dynamic system. This is known for several nuclear pro-
teins, but the presence of a high mobility state at different time
scales had not been demonstrated for the master regulator of NR
action, RXR. According to our results, compared to RAR, themo-
bility of RXR covers a wider range and its activation-induced
changes are more transient. This flexibility and large dynamic
range fits well with the role of RXR as a promiscuous partner. Its
carrier-like behavior, providing a docking surface for coregulators
and regulatory complexes, makes continuous availability impor-
tant. This can be achieved if the transient nature of ligand and
DNA binding is added to the hit-and-run model.
The exact cause of anomalous nuclear diffusion is still an open
question. It should be mentioned that the anomaly parameter of
the slower component of RXR (in the case of using the two-com-
ponent anomalous diffusion model) showed superdiffusion (
1) (see Fig. S2E and F and Table S1 in the supplemental material).
This could be the reflection of short-range directed diffusion of
RXR scanning through the available DNA elements with nonspe-
cific binding or a locally directed “flow” of chromatin segments
together with the bound receptor. Because SPIM-FCS offers the
possibility of measuring directed flow through pixel-pixel cross-
correlation analysis, it might offer answers to this question by
providing high-resolution pictures of the receptor’s activity in the
nuclei of single cells.
The model emerging from these studies is rather dynamic and
compatible with a “hit-and-run,” or rather “scan-and-stop,” sce-
nario inwhichRXR’s nuclearmobility is dependent principally on
coactivator, receptor, and chromatin binding.
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